Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TC-G203 in GPC3-Positive Recurrent/Metastatic Solid Tumors
NCT07242417Phase 1Recruiting
- Sponsor
- Beijing Gaobo Hospital
- Start
- Dec 2025
- Primary completion
- Dec 2026
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of TC-G203 in solid tumor and hepatocellular carcinoma (HCC), sponsored by Beijing Gaobo Hospital. Primary endpoints: Incidence of Dose-Limiting Toxicities at 28 days and Maximum Tolerated Dose at 28 days. Started Dec 2025; status: recruiting.
02
Drugs
TC-G203
03
Conditions
solid tumorhepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT07242417.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07242417.